secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001810560-25-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences PRIME Phase 1b CKD study hits endpoints; Gemini reduces inflammation in high-background patients
--------------------------------------------------------------------------------

- Gemini met primary safety endpoint; well-tolerated at target dose with only mild Grade I events.
- In patients with high background inflammation (≈50%), Gemini significantly reduced IL-1β, TNF-α, IL-6, IL-10, IL-1RA vs placebo (p<0.01) through 7 days.
- Gemini restored normal cellular response to LPS/HMGB1 stimuli in high-background PBMCs, reversing immunoparalysis (IL-1β p<0.0001).
- Company scheduled End of Phase 1 meeting with FDA later in 2025 to discuss advancement.
- 40 patients enrolled across 5 dose cohorts in 3 US clinics; data webcast on Sept 10, 2025 at 8:30 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000181056025000006/0001810560-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000181056025000006/revb-20250909.htm
  HTML page:      https://secwatch.observer/filing/0001810560-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer